Tarik Asselah

Summary

Country: France

Publications

  1. ncbi request reprint [Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]
    Tarik Asselah
    Service d Hépatologie et Unité INSERM CRB3, Universite Paris VII
    Gastroenterol Clin Biol 30:1281-95. 2006
  2. doi request reprint Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Liver Int 32:88-102. 2012
  3. ncbi request reprint Sofosbuvir for the treatment of hepatitis C virus
    Tarik Asselah
    Universite Paris Diderot Paris 7, Assistance Publique Hopitaux de Paris, Hopital Beaujon, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Service d Hepatologie, Inserm Unité 773, 100 bd du Général Leclerc, 92110, Clichy and Paris, France 33 0 140875579 33 0 147309440
    Expert Opin Pharmacother 15:121-30. 2014
  4. doi request reprint Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B
    Tarik Asselah
    INSERM, U 773, CRB3, Hopital Beaujon, AP HP, Universite Paris Diderot, 100 Boulevard du General Leclerc, 92110 Clichy, France
    Clin Liver Dis 17:445-50. 2013
  5. doi request reprint Interferon free therapy with direct acting antivirals for HCV
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 33:93-104. 2013
  6. doi request reprint Interferon stimulated genes and hepatitis C virus infection
    Tarik Asselah
    INSERM, UMR773, Team Viral hepatitis, Centre de Recherche Bichat Beaujon, Paris, France
    J Interferon Cytokine Res 32:557-62. 2012
  7. doi request reprint Triple therapy with boceprevir or telaprevir for prior HCV non-responders
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, 100 bd du Général Leclerc, 92110 Clichy, France
    Best Pract Res Clin Gastroenterol 26:455-62. 2012
  8. doi request reprint IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    J Hepatol 56:527-32. 2012
  9. ncbi request reprint In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
    Tarik Asselah
    INSERM U773, Centre de Recherche CRB3, Paris, 75018, France
    J Pathol 221:264-74. 2010
  10. pmc Gene expression and hepatitis C virus infection
    T Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Paris, France
    Gut 58:846-58. 2009

Detail Information

Publications80

  1. ncbi request reprint [Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]
    Tarik Asselah
    Service d Hépatologie et Unité INSERM CRB3, Universite Paris VII
    Gastroenterol Clin Biol 30:1281-95. 2006
    ..In this article we present a comprehensive review of post-transplant hepatitis C virus infection; in particular fibrosis progression and the major challenges according to treatment...
  2. doi request reprint Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Liver Int 32:88-102. 2012
    ..The aim of this review is to summarize mechanisms of action and results obtained with DAAs...
  3. ncbi request reprint Sofosbuvir for the treatment of hepatitis C virus
    Tarik Asselah
    Universite Paris Diderot Paris 7, Assistance Publique Hopitaux de Paris, Hopital Beaujon, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Service d Hepatologie, Inserm Unité 773, 100 bd du Général Leclerc, 92110, Clichy and Paris, France 33 0 140875579 33 0 147309440
    Expert Opin Pharmacother 15:121-30. 2014
    ....
  4. doi request reprint Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B
    Tarik Asselah
    INSERM, U 773, CRB3, Hopital Beaujon, AP HP, Universite Paris Diderot, 100 Boulevard du General Leclerc, 92110 Clichy, France
    Clin Liver Dis 17:445-50. 2013
    ..The choice of appropriate pharmacotherapy is critical in altering the course of the infection and reducing the costs associated with the management of chronic hepatitis B. ..
  5. doi request reprint Interferon free therapy with direct acting antivirals for HCV
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 33:93-104. 2013
    ....
  6. doi request reprint Interferon stimulated genes and hepatitis C virus infection
    Tarik Asselah
    INSERM, UMR773, Team Viral hepatitis, Centre de Recherche Bichat Beaujon, Paris, France
    J Interferon Cytokine Res 32:557-62. 2012
    ..Furthermore, improved technology and analytical procedures and the use of large numbers of patients for validation are needed...
  7. doi request reprint Triple therapy with boceprevir or telaprevir for prior HCV non-responders
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, 100 bd du Général Leclerc, 92110 Clichy, France
    Best Pract Res Clin Gastroenterol 26:455-62. 2012
    ..The aim of this review is to summarize results obtained with Boceprevir or Telaprevir triple therapy for prior HCV experienced patients (non-responders and relapsers)...
  8. doi request reprint IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    J Hepatol 56:527-32. 2012
    ..However, there are few data on HCV genotype 4 (HCV-4) infection. We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity...
  9. ncbi request reprint In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
    Tarik Asselah
    INSERM U773, Centre de Recherche CRB3, Paris, 75018, France
    J Pathol 221:264-74. 2010
    ..This lack of gene induction may be explained by the inhibiting action of HCV per se (as suggested by in vitro studies) and/or by our finding of the localized nature of hepatocyte ER stress...
  10. pmc Gene expression and hepatitis C virus infection
    T Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Paris, France
    Gut 58:846-58. 2009
    ..This paper reviews the published literature on gene expression associated with HCV infection (HCV infection, fibrosis progression), and also according to response to treatment...
  11. pmc Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Paris, France
    Liver Int 30:1259-69. 2010
    ..The goal of this review is to present the mechanisms of non-response, to overcome it and to identify factors that can help to predict the response to anti-HCV therapy...
  12. ncbi request reprint Clevudine: a promising therapy for the treatment of chronic hepatitis B
    Tarik Asselah
    Universite Paris 7 Denis Diderot, Hopital Beaujon, Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U773
    Expert Opin Investig Drugs 17:1963-74. 2008
    ..This article reviews chronic HBV and its therapy options. Specifically, it describes clevudine's potent and sustained antiviral activity as observed in vitro and in vivo...
  13. doi request reprint New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, and Service d Hépatologie, Hopital Beaujon, Clichy, France
    Liver Int 31:68-77. 2011
    ..There is ongoing development of new molecules such as HCV enzyme inhibitors. The aim of this review is to summarize the results obtained with DAAs: protease and polymerase inhibitors...
  14. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Hopital Beaujon, Service d Hepatologie, AP HP, 92110 Clichy
    Rev Prat 61:45-51. 2011
    ..Telbivudine is more potent and has a lower rate of resistance than lamivudine but the resistance rate is significantly higher than other approved drugs. Tenofovir has a potent antiviral effect with a good resistance profile...
  15. doi request reprint Protease and polymerase inhibitors for the treatment of hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Service d Hepatologie, Hopital Beaujon, Clichy, France
    Liver Int 29:57-67. 2009
    ..The development of new molecules such as HCV enzyme inhibitors is ongoing. The aim of this review is to summarize results obtained with STATC: protease and polymerase inhibitors...
  16. ncbi request reprint A sprint to increase response to HCV treatment: expectancies but caution
    Tarik Asselah
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    J Hepatol 55:1154-8. 2011
    ..The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies...
  17. doi request reprint [Treatment of chronic hepatitis B]
    T Asselah
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, INSERM U773 CRB3, Université Denis Diderot Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 32:749-68. 2008
    ..More potent drugs and new combinations as well as understanding the mechanisms of viral resistance should be evaluated to improve the efficacy of treatment...
  18. ncbi request reprint Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
    T Asselah
    Service d Hepatologie, Pôle des Maladies de l Appareil Digestif and INSERM U773, CRB3, University of Paris VII, AP HP Beaujon Hospital, Clichy, France
    Gut 57:516-24. 2008
    ..Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of this study was to identify a liver gene signature to predict sustained virological response in patients with CHC...
  19. doi request reprint Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
    ..We assessed the influence of combination therapy on the risk of HCC, liver-related complications (ascites, variceal bleeding), and liver-related death (or liver transplantation)...
  20. pmc Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C
    Emilie Estrabaud
    INSERM, UMR1149, Team Physiopathology and Treatment of Viral Hepatitis, Centre de Recherche sur l Inflammation, BP 416, Paris, France
    J Virol 88:6394-402. 2014
    ..The association between miR-122 and IFNL3 was stronger than the association between miR-122 and response to treatment. miR-122 may play a role in the early viral decline that is dependent on IFNL3 and the innate immune response...
  21. ncbi request reprint High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy
    Rami Moucari
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, AP HP, Universite Paris VII, Clichy, France
    J Hepatol 46:596-604. 2007
    ..To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of trials, who were relapsers or non-responders to interferon and ribavirin combination...
  22. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Service d Hepatologie, INSERM CRB3, Universite Paris VII, Hopital Beaujon, Clichy 92
    Presse Med 35:327-34. 2006
    ..They induce a sustained response after withdrawal of therapy in only a minority of patients and therefore the treatment needs to be indefinitely administered in the majority of patients...
  23. doi request reprint Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy F 92110, France
    Gastroenterology 134:416-23. 2008
    ..Our study was designed to test the association between insulin resistance (IR) and hepatitis C virus (HCV) genotypes, serum HCV RNA level and liver fibrosis stage in a large prospective cohort of chronic hepatitis C (CHC) patients...
  24. doi request reprint Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..HBsAg loss was observed in three patients, all with SVR...
  25. ncbi request reprint Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    Institut National de la Sante et de la Recherche Medicale, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Paris, France
    Hepatology 51:1122-6. 2010
    ..7%, 95% confidence interval 99.1-100). In relapse patients, serum HCV-RNA levels were 5.623 +/- 0.748, 4.979 +/- 0.870, and 5.216 +/- 0.758 log(10) IU/mL at baseline, W+12, and W+24, respectively...
  26. ncbi request reprint Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin
    Valerie Paradis
    Service d anatomie pathologie, Hopital Beaujon, and CNRS UMR 8149, Clichy, France
    Gastroenterology 130:2189-97. 2006
    ..We used this approach to monitor the kinetics of serum proteome in patients with chronic hepatitis C virus infection receiving a standard bitherapy regimen to predict treatment response...
  27. doi request reprint Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
    Sarah Maylin
    Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterology 135:821-9. 2008
    ..It is unclear whether hepatitis C virus (HCV) is eradicated in patients with chronic hepatitis C who achieved a sustained virologic response (SVR)...
  28. ncbi request reprint Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Antivir Ther 14:501-11. 2009
    ....
  29. pmc Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009
    ..Viral eradication in chronic hepatitis C patients with sustained virological response (SVR) after interferon (IFN) therapy remains controversial...
  30. doi request reprint Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773, Universite Paris Diderot, 92110 Clichy, France Electronic address
    J Clin Virol 58:401-7. 2013
    ..We investigated whether serum-based monitoring of hepatitis B surface antigen (HBsAg) and HBV-DNA in asymptomatic HBeAg(-) patients could distinguish these groups...
  31. doi request reprint High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, 100 Boulevard du General Leclerc, 92100 Clichy, France
    J Hepatol 50:1084-92. 2009
    ..To assess the HBsAg seroconversion rate and its impact on the long-term outcome in chronic hepatitis B patients treated with conventional interferon, and to analyze the serum HBsAg concentration prior to seroconversion...
  32. ncbi request reprint Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C
    David Saadoun
    Service de Médecine Interne and CNRS UMR 7087, Hopital Pitie Salpetriere, Paris, France
    Hepatology 43:1337-45. 2006
    ..001), and steatosis higher than 10% (P = .04). In conclusion, our study shows an independent association between cryoglobulin and steatosis as well as advanced fibrosis...
  33. doi request reprint The role of HBsAg quantification for monitoring natural history and treatment outcome
    Michelle Martinot-Peignoux
    INSERM, U 773, CRB3, Universite Paris Diderot, Hopital Beaujon, Clichy, France
    Liver Int 33:125-32. 2013
    ..In clinical practice, HBsAg quantification is a simple and reproducible tool that can be used in association with HBV DNA to classify patients during the natural history of HBV and to monitor therapy...
  34. doi request reprint Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy
    Sarah Maylin
    Service de Microbiologie, Universite Paris VII, Faculté de Médecine Denis Diderot, Hopital Bichat, Paris, France
    J Clin Virol 53:43-7. 2012
    ..Correlation between hepatic HCV-RNA and serum HCV-RNA, severity of liver disease and response to therapy is poorly known...
  35. ncbi request reprint Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C
    Tarik Asselah
    Service d hépatologie and INSERM CRB3, AP HP Hôpital Beaujon, University of Paris VII, Paris, France
    Gastroenterology 129:2064-75. 2005
    ....
  36. ncbi request reprint Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study
    Pierre Bedossa
    Service d Anatomie Pathologique, CNRS UMR 8149, Clichy, France
    Hepatology 46:380-7. 2007
    ..In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor...
  37. pmc Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue
    Tarik Asselah
    Service d Hépatologie and Institut National de la Santé et de la Recherche Médicale INSERM U733, CRB3, Universite Paris Diderot, Assistance Publique Hopitaux de Paris, Hopital Beaujon, Clichy, France
    Hepatology 48:953-62. 2008
    ..In chronic hepatitis C liver samples, a lower or higher expression of a IL8 was found depending on whether the controls were obtained percutaneously or surgically...
  38. ncbi request reprint Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection
    Pierre Emmanuel Rautou
    Service d hépatologie and INSERM CRB3, University of Paris VII, Hopital Beaujon, Clichy, France
    Eur J Gastroenterol Hepatol 18:1019-22. 2006
    ..We conclude that the combination of PegIFN plus ribavirin may induce suppression of both viral infections...
  39. doi request reprint Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C
    Ana Carolina Cardoso
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, APHP, University of Paris 7, Clichy, France
    Liver Int 32:612-21. 2012
    ..A secondary analysis was performed to assess whether or not alanine aminotransferase (ALT) levels would impact on the accuracy of TE...
  40. ncbi request reprint Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection
    Ivan Bieche
    Laboratoire de Génétique Moléculaire UPRES EA 3618, Faculte des Sciences Pharmaceutiques et Biologiques, Universite Paris V, Paris, France
    Virology 332:130-44. 2005
    ..Some of the genes identified here could form the basis for new approaches aimed at refining IFN-based therapies for chronic HCV infection...
  41. doi request reprint Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773 and Service d Hépatologie Hôpital Beaujon APHP, Universite Paris Diderot, 92110 Clichy, France
    J Hepatol 58:1089-95. 2013
    ..Therefore, we investigated these relationships in a large cohort of unselected, well-characterized, treatment-naïve CHB patients...
  42. ncbi request reprint Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma
    Chiara Viola
    Service d Hepatologie, INSERM CRB3, University of Paris VII, Hopital, Beaujon, Clichy 92 110, France
    World J Gastroenterol 12:4911-3. 2006
    ..Many HCCs grow slowly, and the growth rate of recurrent tumors in patients receiving immunosuppressive therapy is significantly greater than that of those who do not receive immunosuppressive therapy...
  43. ncbi request reprint Interferon therapy for chronic hepatitis B
    Tarik Asselah
    Service d Hepatologie, INSERM U773, CRB3, University of Paris VII, Hopital Beaujon, 92110 Clichy, France
    Clin Liver Dis 11:839-49, viii. 2007
    ..This article summarizes the results obtained with interferon alfa and pegylated interferon alfa, as monotherapy and in combination with lamivudine, in the treatment of chronic hepatitis B...
  44. ncbi request reprint Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C
    Tarik Asselah
    Service d Hépatologie and INSERM U773, CRB3, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Semin Liver Dis 27:13-27. 2007
    ..This article reviews genetic, genomic, and proteomic aspects associated with the natural history of HCV infection (i.e., viral clearance, fibrosis progression) and the response to therapy...
  45. pmc Changes in autophagic response in patients with chronic hepatitis C virus infection
    Pierre Emmanuel Rautou
    Service d Hepatologie, Hopital Beaujon, Assistance Publique Hopitaux de Paris, Clichy, France
    Am J Pathol 178:2708-15. 2011
    ..Neither genotype nor viral load influenced the autophagy level. In conclusion, autophagy is altered in hepatocytes from CHC patients, likely due to a blockade of the last step of the autophagic process...
  46. doi request reprint Genomics and HCV infection: progression of fibrosis and treatment response
    Emilie Estrabaud
    INSERM, UMR773, Team Viral hepatitis, Centre de Recherche Bichat Beaujon, BP 416, F 75018 Paris, France
    J Hepatol 57:1110-25. 2012
    ..Recent findings on the IL-28B polymorphism and its application in clinical practice will also be discussed...
  47. pmc SCG10 expression on activation of hepatic stellate cells promotes cell motility through interference with microtubules
    Valerie Paradis
    Department of Pathology, INSERM U773, the Serviced Hépatologie, Beaujon Hospital, AP HP, University Paris Diderot, Paris, France
    Am J Pathol 177:1791-7. 2010
    ..SCG10 may represent a potential molecular target for anti-fibrosis therapies...
  48. pmc Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy
    Liana Codes
    Service d Hepatologie, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Gut 56:390-5. 2007
    ..The aim of this study was to evaluate the severity of chronic hepatitis C in women, in relation to the menopause, steatosis and hormone replacement therapy (HRT)...
  49. ncbi request reprint [Chronic hepatitis B: which patients should be treated and how?]
    Tarik Asselah
    Hepatologie, INSERM U481, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 29:374-83. 2005
  50. doi request reprint Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT
    Maxime Ronot
    Unit for Training and Research in Medicine, Universite Paris 7 Denis Diderot, Paris, France
    Radiology 256:135-42. 2010
    ..To prospectively assess the utility of perfusion computed tomography (CT) for differentiating minimal from intermediate fibrosis in treatment-naïve patients with chronic hepatitis C virus (HCV) infection...
  51. ncbi request reprint Multifactorial aetiology of hepatic infarction: a case report with literature review
    Sven Francque
    Service d Hépatologie and INSERM U481, Hopital Beaujon, Clichy, France
    Eur J Gastroenterol Hepatol 16:411-5. 2004
    ..Because hepatic infarction is usually explained by the concurrence of several factors impairing the hepatic blood supply, an extensive search for associated conditions is necessary even when a conspicuous cause is present...
  52. ncbi request reprint The current status of antiviral therapy of chronic hepatitis B
    Tarik Asselah
    Seroice d Hépatologie and INSERM CRB3, Unioersity Paris 7, Hopital Beaujon, AP HP, Clichy, France
    J Clin Virol 34:S115-24. 2005
    ....
  53. ncbi request reprint Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy
    David Saadoun
    Hopital Pitie Salpetriere, Paris, France
    Arthritis Rheum 52:2917-25. 2005
    ....
  54. ncbi request reprint [Hepatitis B: clinical application of HBsAg quantification]
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773, Université Paris Diderot Service d hépatologie, Hopital Beaujon, Clichy, France
    Ann Biol Clin (Paris) 71:19-26. 2013
    ..In clinical practice, HBsAg quantification is a simple and reproducible worthwhile tool that can be used in association with HBV DNA to classify patients during HBV infection and to monitor therapy...
  55. doi request reprint HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients
    Michelle Martinot-Peignoux
    INSERM U773 CRB3, Universite Paris Diderot, Paris, France
    Clin Liver Dis 17:399-412. 2013
    ..In clinical practice qHBsAg is a simple and reproducible tool that may be used in association with HBV-DNA to classify patients during the natural history of HBV and to monitor therapy. ..
  56. ncbi request reprint Acute hepatitis E with severe jaundice: report of three cases
    Rami Moucari
    Hepatology Department and INSERM U773, CRB3, University of Paris VII, Beaujon Hospital, Clichy, France
    Eur J Gastroenterol Hepatol 19:1012-5. 2007
    ..HEV-RNA detection by real-time reverse transcriptase-PCR is a very efficacious diagnostic tool in anti-HEV immunoglobulin-M-negative cases...
  57. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Service d Hepatologie, INSERM U481, Hopital Beaujon, 92110 Clichy
    Gastroenterol Clin Biol 28:1215-27. 2004
  58. ncbi request reprint [Chronic hepatitis C: what to do if the first treatment failed?]
    Tarik Asselah
    Service d Hepatologie, INSERM U481, Centre de Recherche Claude Bernard sur les Hépatites Virales, Hopital Beaujon, 92118 Clichy
    Gastroenterol Clin Biol 26:B50-9. 2002
  59. ncbi request reprint [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]
    Rami Moucari
    Pôle des Maladies de l Appareil Digestif, Service d Hépatologie et INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy
    Gastroenterol Clin Biol 31:643-54. 2007
    ..Insulin resistance and steatosis, appear to be associated with fibrosis progression and impairment of sustained response to antiviral treatment...
  60. ncbi request reprint Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients
    Cédric Laouénan
    INSERM, IAME, UMR 1137, University Paris Diderot, Sorbonne Paris Cité, Paris, France AP HP, Hopital Bichat, Department of Biostatistics, Paris, France
    Antimicrob Agents Chemother 58:5332-41. 2014
    ....
  61. ncbi request reprint Long-term outcome of hepatitis C infection after bone marrow transplantation
    Regis Peffault De Latour
    Service d hématologie greffe de moelle, the Université Paris VII, Paris, France
    Blood 103:1618-24. 2004
    ..Systematic detection of HCV infection, liver biopsy, and therapeutic intervention are therefore warranted in long-term marrow transplant recipients...
  62. doi request reprint Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites
    Thomas Sersté
    Service d Hepatologie, Hôpital AP HP Beaujon, Clichy, France
    Liver Int 31:494-8. 2011
    ..The aim of this prospective study was to investigate the presence of bactDNA in AF and serum among cirrhotic outpatients with non-neutrocytic ascites...
  63. ncbi request reprint Acute pulmonary embolism: a rare complication of a large non-parasitic hepatic cyst
    Sophie Buyse
    Fédération d Hépato Gastroentérologie et INSERM U481, Service de Radiologie, Service d Anatomie Pathologique, Service de Chirurgie viscérale and Service de Médecine Interne, Hopital Beaujon, Clichy, France
    Eur J Gastroenterol Hepatol 16:1241-4. 2004
    ..The patient was treated with heparin. Surgical evacuation of the cyst using the 'fenestration' technique was also performed. There was no recurrent pulmonary embolism or hepatic cyst during a 1-year follow-up period...
  64. ncbi request reprint Fibrosis and disease progression in hepatitis C
    Patrick Marcellin
    Service d Hépatologie and INSERM U 481, Hopital Beaujon, Clichy, France
    Hepatology 36:S47-56. 2002
    ..Repeating the liver biopsy, 3 to 5 years after an initial biopsy is the most accurate means of assessing the progression of fibrosis...
  65. ncbi request reprint CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients
    Vivien Beziat
    INSERM UMR S 945, Hopital Pitie Salpetriere, Paris, France
    Eur J Immunol 42:447-57. 2012
    ..Together, these findings shed new light on how the human NK-cell compartment adjusts to HCMV infection resulting in clonal expansion and differentiation of educated and polyfunctional NK cells...
  66. ncbi request reprint [Treatment of chronic hepatitis B]
    Patrick Marcellin
    Service d hépatologie et Inserm U481, Hopital Beaujon, 92110 Clichy
    Rev Prat 55:624-32. 2005
    ..However, one may expect that their use in monotherapy could not induce a high rate of sustained response and that long-term therapy or combination should be needed to improve efficacy and/or reduce resistance...
  67. doi request reprint Mechanisms of non-response to antiviral treatment in chronic hepatitis C
    Stephane Chevaliez
    National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U955, Hopital Henri Mondor, Universite Paris Est, Creteil, France
    Clin Res Hepatol Gastroenterol 35:S31-41. 2011
    ..The goal of this review is to discuss mechanisms involved in the non-response to current and future standard treatments...
  68. doi request reprint Allogeneic hematopoietic cell transplant in HCV-infected patients
    Regis Peffault De Latour
    Service d Hématologie Greffe, Hopital Saint Louis, 75475 Paris, France
    J Hepatol 48:1008-17. 2008
    ..The pathophysiology of liver fibrosis is discussed as well as the present recommended therapy in this particular population...
  69. ncbi request reprint Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris VII, AP HP, CHU Beaujon, Clichy, France
    J Hepatol 48:200-7. 2008
    ..Mortality related to HCV and HBV infections was estimated in France...
  70. ncbi request reprint Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues
    Ivan Bieche
    INSERM, UMR735, St Cloud, F 92210 Centre Renè Huguenin, FNCLCC, St Cloud, F 92211, France
    Pharmacogenet Genomics 17:731-42. 2007
    ....
  71. ncbi request reprint Prolonged cholestasis and ductopenia associated with tenoxicam
    Viviane Trak-Smayra
    Department of Pathology, Beaujon Hospital, 100 Boulevard du General Leclerc, 92118 Clichy Cedex, France
    J Hepatol 39:125-8. 2003
    ..and (3) the presence of ductopenia contrasted with the "clinical recovery" of the disease suggesting accessory bile drainage by cholangioles or partial reconstruction of the biliary tree...
  72. ncbi request reprint Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response
    Emilie Estrabaud
    Service d Hépatologie and INSERM U773 CRB3, Beaujon Hospital, University Paris VII, France
    J Hepatol 55:1150-3. 2011
    ....
  73. ncbi request reprint Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study
    Bertrand Condat
    Service d Hepatologie, Fédération Médico chirurgicale d Hépatogastroentérologie, Hopital Beaujon, AP HP, Paris, France
    Hepatology 37:1302-8. 2003
    ..MR cholangiography coupled with MR portography is an effective noninvasive examination for simultaneous visualization of bile ducts and their relationship to the cavernoma...
  74. ncbi request reprint Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine
    Patrick Marcellin
    Service d Hepatologie, INSERM CRB3, University of Paris VII, Hopital Beaujon, Clichy, France
    Hepatol Res 37:S55-61. 2007
    ..PEG IFN, administered for 48 weeks, gives an overall sustained response rate of approximately 30%. Two large randomized controlled trials have conducted to registration of PEG IFN-alpha-2a in the treatment of chronic hepatitis B...
  75. ncbi request reprint [What does chronic hepatitis C steatosis mean?]
    Tarik Asselah
    Gastroenterol Clin Biol 27:1073-5. 2003
  76. ncbi request reprint Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C
    Bertrand Condat
    Service d Hepato Gastroenterologie, hôpital Saint Camille, Bry sur Marne, France
    Eur J Gastroenterol Hepatol 18:287-9. 2006
    ..Clinicians should be aware of this potential complication when evaluating the ratio benefit/risk of treatment in patients with chronic hepatitis C infection...
  77. ncbi request reprint Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
    Jean Pierre Bronowicki
    Department of Hepatology and Gastroenterology, INSERM U724, CHU de Nancy, Vandoeuvre les Nancy, France
    Gastroenterology 131:1040-8. 2006
    ..We aimed to investigate the role of ribavirin in HCV clearance during therapy and to evaluate the consequences of ribavirin discontinuation in patients infected with genotype 1 hepatitis C who cleared HCV RNA at week 24...
  78. ncbi request reprint Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data
    Gioacchino Leandro
    IRCSS de Bellis, Castellana Grotte, Italy
    Gastroenterology 130:1636-42. 2006
    ..We evaluated the association between steatosis and fibrosis and their common correlates in persons with CHC and in subgroup analyses according to hepatitis C virus (HCV) genotype and body mass index...
  79. ncbi request reprint Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy
    Manuela G Neuman
    Division of Clinical Pharmacology, E 240, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    Cytokine 17:108-17. 2002
    ....
  80. ncbi request reprint Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B
    Patrick Marcellin
    J Hepatol 43:920-3. 2005